SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

11 Nov 2022 Evaluate
A fair growth of 19.43% in the revenue at Rs. 2361.27 millions was reported in the September 2022 quarter as compared to Rs. 1977.08 millions during year-ago period.The Total revenue for the quarter ended September 2022 of  Rs. 325.66  millions  grew by 172.61% from Rs. 119.46 millions.Operating profit surged to 475.20 millions from the corresponding previous quarter of 207.59 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 2361.27 1977.08 19.43 4684.59 3731.10 25.56 8056.00 8135.63 -0.98
Other Income 67.94 28.43 138.97 109.08 57.42 89.97 147.58 128.41 14.93
PBIDT 475.20 207.59 128.91 795.98 392.89 102.60 1009.33 1483.12 -31.95
Interest 1.62 2.47 -34.41 3.48 5.13 -32.16 9.47 10.93 -13.36
PBDT 473.58 205.12 130.88 792.50 387.76 104.38 999.86 1472.19 -32.08
Depreciation 32.87 42.76 -23.13 78.79 90.37 -12.81 169.49 201.26 -15.79
PBT 440.71 162.36 171.44 713.71 297.39 139.99 830.37 1270.93 -34.66
TAX 115.05 42.90 168.18 186.50 75.51 146.99 214.43 337.90 -36.54
Deferred Tax -8.95 -4.82 85.68 -14.24 -13.88 2.59 -11.86 -10.38 14.26
PAT 325.66 119.46 172.61 527.21 221.88 137.61 615.94 933.03 -33.98
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 20.12 10.50 91.67 16.99 10.53 61.36 12.53 18.23 -31.27

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×